Clinical Trial Phases Explained: I, II, III, IV

Phase I trials test safety and dosage in a small group of patients, Phase II evaluates effectiveness and side effects in a larger group, Phase III compares the new treatment against standard care in large, often randomised, populations, and Phase IV monitors long-term safety after regulatory approval. Each phase builds on the evidence gathered in the one before it.

The trial phase you're offered affects how much is known about the treatment and how intensive participation will be. Discussing the phase with your care team helps set realistic expectations about benefits, risks, and time commitment.

Trial registries and information sheets always state the phase clearly. Screening for a phase-specific trial involves confirming your cancer type, prior treatments, and general health meet that study's defined criteria.

All cancer types pass through this phased research pathway, though the number of trials available at each phase varies. Rare cancers or heavily pre-treated cancers often have more early-phase (Phase I/II) options, while common cancers with existing standard treatments may have more Phase III trials comparing refinements to care.

Expect more frequent visits and monitoring in earlier-phase trials, and a schedule closer to standard care in later phases. Randomisation in Phase III trials means you may not receive the experimental treatment, which is worth discussing with your oncologist beforehand.